Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Gains from Investment Securities (2016 - 2022)

Edesa Biotech's Gains from Investment Securities history spans 9 years, with the latest figure at $500083.0 for Q2 2022.

  • For Q2 2022, Gains from Investment Securities fell 71.79% year-over-year to $500083.0; the TTM value through Jun 2022 reached $500083.0, down 71.79%, while the annual FY2022 figure was $408059.0, 77.03% down from the prior year.
  • Gains from Investment Securities for Q2 2022 was $500083.0 at Edesa Biotech, down from $2.3 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.3 million in Q1 2022 and bottomed at $315123.0 in Q4 2018.
  • The 5-year median for Gains from Investment Securities is $430000.0 (2020), against an average of $859183.8.
  • The largest annual shift saw Gains from Investment Securities surged 39290.38% in 2018 before it tumbled 71.79% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at $315123.0 in 2018, then increased by 1.4% to $319526.0 in 2019, then skyrocketed by 34.57% to $430000.0 in 2020, then soared by 313.07% to $1.8 million in 2021, then plummeted by 71.85% to $500083.0 in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Gains from Investment Securities are $500083.0 (Q2 2022), $2.3 million (Q1 2022), and $1.8 million (Q3 2021).